Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

22.39 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Love, Money, and Stocks
Via The Motley Fool
Which S&P500 stocks are the most active on Tuesday?
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Tuesday. Discover the stocks that are generating the highest... 
Via Chartmill
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
From Berger Montague
Via GlobeNewswire
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich
Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion. 
Via Benzinga
Topics Government
Exposures Political
3 Things You Need to Know If You Buy Pfizer Today
Via The Motley Fool
Health Insurance ETFs in Focus as RFK Jr Takes Over HHS
Robert F. Kennedy Jr. has taken office as HHS secretary, which could impact the healthcare sector, including ETFs with exposure to insurers like UnitedHealth and Elevance Health. 
Via Benzinga
Topics ETFs
Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally. 
Via Benzinga
3 Magnificent Stocks to Buy That Are Near 52-Week Lows
Via The Motley Fool
Pfizer's Talzenna/Xtandi Combo Improves Survival Outcomes In Metastatic Castration-Resistant Prostate Cancer
Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS gain in HRR-mutated cases. 
Via Benzinga
Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump's Secretary Of Health: Health Care Stocks To Watch
The U.S. Senate voted on Thursday to confirm President Donald Trump's nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services. 
Via Benzinga
Topics Government
Exposures Political
Are Investors Being Too Paranoid About Pfizer Stock?
Via The Motley Fool
Pfizer's Options Frenzy: What You Need to Know
Via Benzinga
Is Now a Good Time to Buy the Dip on Pfizer?
Via The Motley Fool
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
From Pfizer Inc.
Via Business Wire
Zoetis (NYSE:ZTS) Posts Q4 Sales In Line With Estimates But Stock Drops
Animal health company Zoetis (NYSE:ZTS) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.7% year on year to $2.32 billion. On the other hand, the company’s full-year revenue... 
Via StockStory
3 Brand-Name, Ultra-High-Yield Dividend Stocks Patient Investors Can Confidently Buy With $300 Right Now
A trio of high-octane income stocks -- sporting an average yield of 6.65% -- can fatten investors' pocketbooks in 2025 (and well beyond). 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
From Pfizer Inc.
Via Business Wire
Earnings To Watch: Zoetis (ZTS) Reports Q4 Results Tomorrow
Animal health company Zoetis (NYSE:ZTS) will be reporting results tomorrow before market open. Here’s what to look for. 
Via StockStory
Organon (OGN) Q4 Earnings Report Preview: What To Look For
Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings tomorrow before market hours. Here’s what investors should know. 
Via StockStory
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
Pfizer and Astellas' Padcev-Keytruda combo showed durable survival benefits in urothelial cancer, with a higher response rate and no new safety concerns. 
Via Benzinga
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
From Pfizer Inc.
Via Business Wire
Explore the S&P500 index on Monday and find out which stocks are the most active in today's session.
Let's have a look at what is happening on the US markets on Monday. Below you can find the most active S&P500 stocks in today's session. 
Via Chartmill
Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them
The list of Super Bowl LIX commercials and the companies behind the Super Bowl ads. 
Via Benzinga
These Stocks Missed on Earnings, But Will Rebound Next Quarter
Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year 
Via MarketBeat
Royalty Pharma Earnings: What To Look For From RPRX
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings tomorrow morning. Here’s what to look for. 
Via StockStory
Better High-Yield Dividend Stock: Pfizer vs. Merck
Via The Motley Fool
3 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Via The Motley Fool
3 Dividend Stocks to Double Up on Right Now
Via The Motley Fool
10 Undervalued Hidden Gem Dividend Stocks For Savvy Investors
Income investors should focus on higher-yielding securities, if they want additional income from their stock portfolios. 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.